Acadia Pharmaceuticals Inc.

Day range

$20.12 – $20.50

Open

$20.30

Prev close

$20.31

Volume

1.23M

Market cap

$3.5B

Shares out

172.31M

P/E

9.20

P/S

3.07

P/B

2.68

P/FCF

24.03

ROE

29.1%

ROA

21.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 22, 2026

• Business developmentsSep 24, 2026

  For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of –1.3 versus a change of –0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)].

• Material agreementsSep 11, 2026

  On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action captioned Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB.

• Shareholder meetingsMay 29, 2026

  The election of three nominees to serve as Class I directors on the Company's Board of Directors until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal, was carried out at the Annual Meeting. The following three Class I directors were elected by the votes indicated: James M. Daly (146,927,745 For, 3,521,002 Withheld), Edmund P. Harrigan, M.D. (128,460,130 For, 21,988,617 Withheld), Adora Ndu, Pharm.D., J.D. (134,540,552 For, 15,908,195 Withheld).

• Executive leadershipMay 1, 2026

  On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the "Company") of her planned retirement. Dr. Thompson has decided to retire for personal reasons. She has committed to continuing in her role as Head of Research and Development for a transitional period until a successor is appointed, after which she intends to remain with the Company as a consultant through the end of 2026.

• Board of directorsMar 5, 2026

  On March 3, 2026, the board of directors (the "Board") of Acadia Pharmaceuticals Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jonathan M. Poole to the Board to fill a vacancy and as a member of the Audit Committee of the Board, effective immediately. Mr. Poole will serve as a Class II director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders.

Days to cover

2.9

Short interest

8.28M

Avg volume

2.83M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
  positiveZacks Investment Research· Oct 21, 2026
• Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
  positiveZacks Investment Research· Oct 13, 2026
• 4 CNS Drug Stocks Worth Watching This World Mental Health Day
  positiveZacks Investment Research· Oct 9, 2026
• Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
  positiveZacks Investment Research· Sep 29, 2026